# Effect of Bifidobacterium longum on cognition and microbiota in post-stroke patients: a single-blinded, controlled trial

**Authors:** Shu-Ting Lin, Te-Hsuan Tung, Yen-Nung Lin, Feng-Hang Chang, Yu Zhi Lian, Chien-Hung Lai, Tsan-Hon Liou, Chi-Chang Huang, Ya-Ling Chen, Jane C.-J. Chao

PMC · DOI: 10.7150/ijms.124024 · 2026-02-11

## TL;DR

This study found that a probiotic, Bifidobacterium longum OLP-01, improved cognitive function and altered gut microbiota in post-stroke patients over 12 weeks.

## Contribution

The novel finding is that Bifidobacterium longum OLP-01 improves cognition and modifies gut microbiota in post-stroke patients.

## Key findings

- The OLP-01 group showed improved Montreal Cognitive Assessment (MoCA) scores.
- The probiotic group had faster Trail-Making Test completion times and better Stroop test accuracy.
- Gut microbiota composition differed between the probiotic and placebo groups.

## Abstract

Stroke is the major leading cause of death globally, and has a high disability rate. Malnutrition, cognitive dysfunction, motor impairment, and gut dysbiosis are observed in stroke patients. Our study explored the effects of Bifidobacterium longum OLP-01, a probiotic from an Olympics gold medalist, on cognitive function and gut microbiota as the primary outcomes, and on nutritional status and physical performance as the secondary outcomes in post-stroke patients. The study was a single-blinded, randomized, placebo-controlled trial. We recruited 22 post-stroke patients. Participants received either placebo (placebo group, n = 10) or 2 × 1010 colony-forming units (CFU) of Bifidobacterium longum OLP-01 powder (OLP-01 group, n = 12) daily for 12 weeks. Nutritional status was assessed using Mini Nutritional Assessment (MNA). Cognitive function was evaluated by Montreal Cognitive Assessment (MoCA), Trail-Making Tests, and Stroop Color Naming Test. Physical performance was measured using Timed Up and Go Test and 6-Minute Walk Test. Blood and stool samples were collected for biochemical and gut microbiota analyses. The OLP-01 group increased MoCA scores, decreased time to completion of Trail-Making Tests, and had greater accuracy on incongruent in Stroop Color Naming Test, but decreased MNA scores within the normal ranges. The cognitive-related gut microbiota strain showed differences between the two groups. Supplementation of Bifidobacterium longum OLP-01 at a dose of 2 × 1010 CFU daily for 12 weeks improved cognitive function and changes gut microbiota, but did not alter physical performance in post-stroke patients.

## Linked entities

- **Diseases:** stroke (MONDO:0005098)
- **Species:** Bifidobacterium longum (taxon 216816)

## Full-text entities

- **Genes:** IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TPSG1 (tryptase gamma 1) [NCBI Gene 25823] {aka PRSS31, TMT, trpA}
- **Diseases:** autoimmune disease (MESH:D001327), falls (MESH:C537863), hemorrhagic (MESH:D006470), Post-stroke (MESH:D020521), TUGT (MESH:D013736), fatigue (MESH:D005221), neuroblastoma (MESH:D009447), neurological deficit (MESH:D009461), colorectal adenocarcinoma (MESH:D003110), hematoma (MESH:D006406), muscle atrophy (MESH:D009133), Inflammatory (MESH:D007249), headache (MESH:D006261), Gut dysbiosis (MESH:D064806), cancer (MESH:D009369), hemorrhagic stroke (MESH:D000083302), depression (MESH:D003866), dementia (MESH:D003704), motor impairment (MESH:D000068079), MoCA (MESH:D003072), disabilities (MESH:D009069), Thrombosis (MESH:D013927), dysphagia (MESH:D003680), subarachnoid hemorrhage (MESH:D013345), PCoA (MESH:D001259), altered level of consciousness (MESH:D003244), brain lesion (MESH:D001927), brain injury (MESH:D001930), Malnutrition (MESH:D044342), death (MESH:D003643), post (MESH:D000094025), COVID-19 (MESH:D000086382), cerebral, spinal, or retinal infarction (MESH:D012173), ischemic stroke (MESH:D002544), aphasia (MESH:D001037), vascular injury (MESH:D057772)
- **Chemicals:** fat (MESH:D005223), maltodextrin (MESH:C008315), lactate (MESH:D019344), triglycerides (MESH:D014280), lipopolysaccharides (MESH:D008070), lipid (MESH:D008055), SCFA (MESH:D005232), B. longum (-), TG (MESH:D013866), Carb (MESH:D002241), corn starch (MESH:D013213)
- **Species:** Veillonella (genus) [taxon 29465], Bifidobacterium bifidum BGN4 (strain) [taxon 484020], Bifidobacterium longum (species) [taxon 216816], Mus musculus (house mouse, species) [taxon 10090], Eubacterium (genus) [taxon 1730], Prevotella (genus) [taxon 838], Bifidobacterium bifidum (species) [taxon 1681], Streptococcus (genus) [taxon 1301], Bifidobacterium longum BORI (strain) [taxon 478445], Rattus norvegicus (brown rat, species) [taxon 10116], Prevotellaceae (family) [taxon 171552], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** SHSY-5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965072/full.md

---
Source: https://tomesphere.com/paper/PMC12965072